Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has completed patient enrolment for the Phase IIa clinical trial for its drug candidate QGC001.
To date, more than 75% of patients have completed the trial. Initial results showed satisfactory patient tolerance, supporting the continuation as planned of Quantum Genomics' clinical development programmes for high blood pressure and heart failure treatment (read the press release of 6 October 2015).
Olivier Madonna, Medical Director of Quantum Genomics, says:
“We began recruiting patients in March 2015 and by early September had enrolled over 50% of the patients we needed. The latest patients recruited should complete the trial in April and the results should be available within the following three months, ahead of our initial timeline. We are now working on preparing the Phase IIb trial which will be multicentric and international. The results will allow us to refine the protocols for further trials.”
As a reminder, this clinical trial is conducted on some 30 patients with high blood pressure and involves four clinical investigation centres in France, under the supervision of Prof. Michel Azizi (Clinical Investigation Centre at Georges Pompidou European Hospital, Paris).
It is a randomised double-blind study, with cross-over, to compare the effects of the product QGC001 (500 mg morning and night) with those of a placebo. It also aims to analyse the pharmacodynamic effects of QGC001 on several hormonal biomarkers.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance et communication
+33 1 53 67 36 73
|ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).